{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:01:19Z","timestamp":1786363279233,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Army Appropriated Funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Malaria is classified as a top-tier infectious disease threat associated with a high risk for mortality among U.S. service members deployed overseas. As malarial drug resistance degrades the efficacy of current gold standard drugs for malarial prophylaxis and treatment, it is vitally important to maintain a robust drug pipeline to discover and develop improved, next-generation antimalarial prevention and treatment tools. The U.S. Army Medical Materiel Development Activity (USAMMDA) manages the medical product development of the malarial drug tafenoquine for malarial prophylaxis to address the threat to U.S. service members. Tafenoquine is an effective prophylactic drug against all parasite life cycle stages and all malaria species that infect humans. Thus, it provides broad capabilities in a single drug for malarial prophylaxis and treatment. Partnerships with industry are a crucial part of USAMMDA\u2019s medical product development strategy, by leveraging their drug development experience and manufacturing capabilities to achieve licensure and commercial availability. Additionally, these partnerships capitalize on expertise in the commercial market and help ensure that USAMMDA successfully translates a Department of Defense capability gap into a commercially available product. This article will highlight the strategies used to move this critical antimalarial drug through the development pipeline.<\/jats:p>","DOI":"10.1093\/milmed\/usz304","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T15:11:54Z","timestamp":1582125114000},"page":"617-623","source":"Crossref","is-referenced-by-count":16,"title":["Army Antimalarial Drug Development: An Advanced Development Case Study for Tafenoquine"],"prefix":"10.1093","volume":"185","author":[{"given":"Victor E","family":"Zottig","sequence":"first","affiliation":[{"name":"U.S. Army Medical Materiel Development Activity, 1430 Veterans Dr., Fort Detrick, MD 21702"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A","family":"Carr","sequence":"first","affiliation":[{"name":"U.S. Army Medical Materiel Development Activity, 1430 Veterans Dr., Fort Detrick, MD 21702"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G","family":"Clarke","sequence":"first","affiliation":[{"name":"U.S. Army Medical Materiel Development Activity, 1430 Veterans Dr., Fort Detrick, MD 21702"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe J","family":"Shmuklarsky","sequence":"first","affiliation":[{"name":"U.S. Army Medical Materiel Development Activity, 1430 Veterans Dr., Fort Detrick, MD 21702"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Kreishman-Deitrick","sequence":"first","affiliation":[{"name":"Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD 20910"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"2020021912200246600_ref1"},{"issue":"12","key":"2020021912200246600_ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0002448","article-title":"United States Military Tropical Medicine: extraordinary legacy, uncertain future","volume":"7","author":"Beaumier","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"2020021912200246600_ref3","first-page":"1","article-title":"Malaria surveillance-United States, 2015","volume":"67","author":"Mace","year":"2015","journal-title":"MMWR"},{"issue":"2","key":"2020021912200246600_ref4","first-page":"2","article-title":"Update: malaria, U.S. armed forces","volume":"25","year":"2017","journal-title":"MSMR"},{"key":"2020021912200246600_ref5"},{"issue":"11","key":"2020021912200246600_ref6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","article-title":"Research and Development spending to bring a single cancer drug to market and revenues after approval","volume":"177","author":"Prasad","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2020021912200246600_ref7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrd.2017.21","article-title":"Clinical trial cycle times continue to increase despite industry efforts","volume":"16","author":"Martin","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2020021912200246600_ref8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1983.03340050071035","article-title":"Walter Reed and yellow fever","author":"Bean","year":"1983","journal-title":"JAMA"},{"key":"2020021912200246600_ref9","first-page":"27","article-title":"Malaria studies aim at drug resistance","volume":"26","author":"Milhous","year":"1990","journal-title":"US Med"},{"issue":"1","key":"2020021912200246600_ref10","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2012.045","article-title":"Prophylaxis of malaria","volume":"4","author":"Schwartz","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2020021912200246600_ref11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0378-4347(00)81111-1","article-title":"Rapid and sensitive quantitative analysis of the new antimalarial N4-[2,6-dimethoxy-4-methyl-5[(3-trifluorome-thyl)phenoxy]-8-quinolinyl]-1,4-pentanediamine in plasma by liquid chromatography and electrochemical detection","volume":"424","author":"Karle","year":"1988","journal-title":"J Chromatogr"},{"issue":"12","key":"2020021912200246600_ref12","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1023\/A:1015842316177","article-title":"Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR238605)","volume":"8","author":"Brueckner","year":"1991","journal-title":"Pharm Res"},{"issue":"6","key":"2020021912200246600_ref13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/00034983.1993.11812809","article-title":"The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605","volume":"87","author":"Peters","year":"1993","journal-title":"Ann Trop Med Parasitol"},{"issue":"5","key":"2020021912200246600_ref14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4269\/ajtmh.1998.58.645","article-title":"First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial","volume":"58","author":"Brueckner","year":"1998","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"2020021912200246600_ref15","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.42.5.1293","article-title":"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-Aminoquinoline antimalarial","volume":"42","author":"Brueckner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021912200246600_ref16","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1086\/315034","article-title":"Randomized dose-ranging study of the safety and efficacy of WR238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand","volume":"180","author":"Walsh","year":"1999","journal-title":"J Infect Dis"},{"key":"2020021912200246600_ref17","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1086\/324081","article-title":"A new primaquine analogue, tafenoquine (WR238605), for prophylaxis against Plasmodium falciparum malaria","volume":"33","author":"Shanks","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020021912200246600_ref18","first-page":"12","article-title":"Addressing full-spectrum product life cycle","author":"Bailey","year":"2018","journal-title":"Combat Casualty Care"},{"key":"2020021912200246600_ref19"},{"issue":"2","key":"2020021912200246600_ref20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of Tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021912200246600_ref21"},{"key":"2020021912200246600_ref22"},{"issue":"3","key":"2020021912200246600_ref23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/cid\/ciy939","article-title":"Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blinded, placebo-controlled phase 1b study","volume":"69","author":"McCarthy","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2020021912200246600_ref24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4269\/ajtmh.15-0245","article-title":"Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American soldiers in Afghanistan","volume":"93","author":"Saunders","year":"2015","journal-title":"Am J Trop Med Hyg"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/185\/Supplement_1\/617\/32524371\/usz304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/185\/Supplement_1\/617\/32524371\/usz304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T15:12:03Z","timestamp":1582125123000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/185\/Supplement_1\/617\/5740680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":24,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,2,19]]},"published-print":{"date-parts":[[2020,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usz304","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2020,1]]}}}